Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 69

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 69
---
 and automatically converted into that certain number of fully paid and nonassessable TELI Common Shares as calculated in accordance with the terms of the Exchange Ratio. It is anticipated that the initial Exchange Ratio is estimated to result in TELI shareholders holding 50% of the issued and outstanding shares of TELI Common Shares.

Merger Consideration and Exchange Ratio.

At the Effective Time, each outstanding share of TELI Common Stock, will be converted into the right to receive such number of shares of common stock of TELO Common Stock, as is calculated in accordance with the Exchange Ratio, but in no instance will the amount of TELO Common Stock issued be greater than the number of outstanding TELO Common Stock as-of the closing date of the Merger. The Exchange Ratio is calculated using the relative company valuations of each of TELO and TELI, as determined by Moore (as further described herein). It is expected that shareholders of TELO will receive one share of TELI Common Stock for each share of TELI Common Stock held (the “Merger Share Consideration”). The TELI Common Stock issued as the consideration will not be registered for trading under the Securities Act.

In addition to the Merger Share Consideration,
certain members of TELI collectively hold warrants to purchase a total of 14,250,000 TELI Common Stock (the “Warrants”).
The Warrants are exercisable upon FDA acceptance of an Investigational New Drug (IND) application for Telomir at $2.00 per share, for
a period of 10-years. At Closing, the Warrants will be converted to warrants to purchase Telomir Common Stock at similar terms as the
Warrants.

Absence of Contingent Consideration

There are no contingent value rights, earnouts, or milestone payments associated with the merger consideration

Exchange Procedures

Pursuant to the terms of the Merger Agreement, prior to or at the Closing, TELI shall designate its transfer agent, or a depository, bank or trust company reasonably acceptable to TELI to act as the exchange agent in connection with the Merger, or the Exchange Agent, and enter into an exchange agreement, in a form reasonably acceptable to TELI, for the payment of the Merger Consideration. Prior to or substantially concurrently with the Effective Time, TELI shall deposit or cause to be deposited with the Exchange Agent, for the benefit of the holders of TELI Common Stock for exchange in